Zhu X, Venkataprasad N, Ivanyi J, Vordermeier H M
MRC Clinical Sciences Centre, Hammersmith Hospital, London, UK.
Immunology. 1997 Sep;92(1):6-9. doi: 10.1046/j.1365-2567.1997.00358.x.
A number of subunit-based vaccine candidates have recently begun to erode the exclusive position of Mycobacterium bovis bacillus Calmette-Guérin (BCG), which gives unpredictable and highly variable protection against tuberculosis. In this paper we investigated the protective capacity of the 19,000 MW and 38,000 MW glyco-lipoproteins of M. tuberculosis expressed by recombinant vaccinia viruses in a mouse Mycobacterium tuberculosis infection model. Both proteins were expressed at high levels by recombinant vaccinia-infected cells. In addition, two inoculations of C57B1/6 mice with either recombinant vaccinia virus significantly reduced the bacterial counts in the lungs of M. tuberculosis H37Rv-infected mice, when compared with the group infected with control virus. This is the first report of protection against tuberculous infection using recombinant vaccinia viruses with results that suggest that secreted glyco-lipoproteins in conjunction with the vaccinia vector represent suitable candidates for further vaccine-related studies.
最近，一些基于亚单位的候选疫苗开始撼动卡介苗（BCG）的独占地位，卡介苗对结核病的保护作用不可预测且差异很大。在本文中，我们在小鼠结核分枝杆菌感染模型中研究了重组痘苗病毒表达的结核分枝杆菌19,000MW和38,000MW糖脂蛋白的保护能力。这两种蛋白在重组痘苗病毒感染的细胞中均高水平表达。此外，与感染对照病毒的组相比，用重组痘苗病毒对C57B1/6小鼠进行两次接种可显著降低结核分枝杆菌H37Rv感染小鼠肺部的细菌数量。这是首次使用重组痘苗病毒预防结核感染的报告，结果表明分泌的糖脂蛋白与痘苗载体结合是进一步疫苗相关研究的合适候选物。
